SR12460
SR12460 is a NEMO-binding domain mimetic and an inhibitor of the IKKβ-NEMO complex with an IC50 of 11.34 μM. SR12460 disrupts the IKKβ-NEMO interaction, thereby inhibiting NF-κB activation, including TNF-α- and LPS-induced NF-κB activation. SR12460 inhibits LPS-induced acute lung inflammation in mice and alleviates inflammatory infiltration, necrosis, and muscle degeneration in a mouse model of Duchenne muscular dystrophy. SR12460 is used for research on acute lung inflammation and Duchenne muscular dystrophy.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2055101-66-9
- Formule: C15H14ClF2N3O
- Masse moléculaire:325.74
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
11.34 μM
|
Inhibition of TNF-α-induced NF-κB activation in human HEK293 cells measured via NF-κB dual-luciferase reporter assay, with 30 minutes of pretreatment followed by 3 hours of TNF-α stimulation.
Inhibition of TNF-α-induced NF-κB activation in human HEK293 cells measured via NF-κB dual-luciferase reporter assay, with 30 minutes of pretreatment followed by 3 hours of TNF-α stimulation.
|
29889904 |
In Vitro
SR12460 (50 μM; 30 min pretreatment, followed by 2 h LPS stimulation) suppresses the expression of multiple LPS-induced NF-κB target genes in Raw 264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Raw 264.7 mouse macrophage cells
-
Concentration:50 μM
-
Incubation Time:30 min pretreatment, followed by 2 h LPS stimulation
-
Result:Significantly inhibited the LPS-induced transcription of the NF-κB target genes cyclooxygenase 2 (COX-2), interleukin-6 (IL-6), interleukin-1β (IL-1β), TNF-α, IκBα, and inducible nitric oxide synthase (iNOS).
-
Cell Line:Raw 264.7 mouse macrophage cells
-
Concentration:25, 50 μM
-
Incubation Time:1 h pretreatment, followed by 24 h LPS stimulation
-
Result:Significantly inhibited LPS-induced IL-6 secretion in a dose-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (female, 8-10 weeks old, 20-30 g, intraperitoneal LPS challenge)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Suppressed LPS-induced expression of NF-κB target genes iNOS, IκBα, COX-2, and IL-6 in lung tissue.
Suppressed only COX-2 expression in liver tissue.
-
Animal Model:C57BL/10ScSn-Dmdmdx/J (mdx) (sex-matched, 3 weeks old at treatment initiation)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; 3 times per week; 4 weeks
-
Result:Reduced the percentage of tibialis anterior muscle area with necrosis and inflammation.
Increased expression of muscle regeneration markers eMyHC and Pax7.
Improved forelimb grip strength normalized to body weight after 4 weeks of treatment.
Chemical Information
-
CAS No. 2055101-66-9
-
Masse moléculaire 325.74
-
Formule C15H14ClF2N3O
-
SMILES
O=C(CNCCC1=CC(F)=CC(F)=C1)NC2=NC=C(C=C2)Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SR12460 Related Classifications
HY-124578 Related Classifications
Powered by Bioz